Recent Advances in Gut Microbiome and Heart Failure
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Microbiology in Human Health and Disease".
Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 14960
Special Issue Editor
Interests: mass spectrometry; biomarkers; metabolomics; proteomics; omics; cardiovascular disease; gut metabolites
Special Issue Information
Dear Colleagues,
Heart failure (HF) is a global epidemic affecting more than 26 million people—a number which is expected to rise. In recent years, sequencing studies have reported that the composition of the intestinal flora between HF patients and healthy individuals is different. For this reason, the human gut microbiota has been identified as a novel risk factor for HF, leading to extensive research regarding the gut–heart axis. Patients with HF have alterations to the gut microbiota as a result of microbial disturbances, possibly aggravating HF through inflammatory responses attributed to HF pathogenesis. Moreso, recent omics technologies have allowed us to appreciate the gut–heart axis via analysis of the gut bacteria and its associated metabolites (such as short-chain fatty acids and trimethylamine N-oxide) through methods including mass spectrometry. Taken together, the analysis of the microbiota and gut biomarkers, and the understanding of the gut–heart axis may lead to the development of innovative diagnostics and therapeutics.
Dr. Muhammad Zubair Israr
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- heart failure
- metabolic disease
- metabolomics
- omics
- microbiome/microbiota
- gut–heart axis
- novel technologies
- biomarkers
- therapeutics